Where the US Biosimilars Market Is Heading and When It Might Get There: 2021 Edition

$99.95

The updated 2021 edition of the publication Where the US Biosimilars Market Is Heading and When It Might Get There is a vital resource for those managing drug benefits, designing medical and pharmacy coverage policies, prescribing biologic medications, and the manufacturers of biosimilars and biologics alike.

Description

The laws establishing the US biosimilar approval pathway were passed in 2010, but the market for biosimilars is only beginning to gain speed. The causes for this slow start are complex and multifactorial. Veteran biosimilar industry journalist and BR&R Content Director Stanton Mehr unravels the competing interests of stakeholders and pragmatically reframes the conversation: How did we arrive at today’s critical juncture in the US biosimilar marketplace? What biosimilar categories will thrive or fail? What dynamic forces may drive a biosimilar future in the US?

This report pragmatically reframes the conversation: How did we arrive at today’s biosimilar marketplace? What biosimilar drug categories will thrive or fail? What dynamic forces may drive a biosimilar future in the US?

The updated 2021 edition of the publication Where the US Biosimilars Market Is Heading and When It Might Get There is a vital resource for those managing drug benefits, designing medical and pharmacy coverage policies, prescribing biologic medications, and the manufacturers of biosimilars and biologics alike.

This 86-page report covers the past, present, and future of the US biosimilar industry. We take an in-depth view into five critical drug categories. We delineate the forcing factors that will allow for future success of biosimilars in the America. This publication also analyzes the competing priorities of each relevant stakeholder, some of which can limit or optimize the biosimilar-related savings obtained by the US health system.

New for 2021:

  • The latest available data on biosimilar uptake throughout the report
  • Views on how biosimilars have now turned the corner in some major treatment areas
  • The employer’s perspective on the need for biosimilars and improved utilization
  • The outlook for biosimilars of low-revenue biologics and rare disease treatments
  • New insights into the Supreme Court’s upcoming ruling on the repeal of the ACA and its affects on the BPCIA

Note: This publication is supplied for personal use only. We are happy to provide discounted pricing for multiple copies.

Reviews

There are no reviews yet.

Be the first to review “Where the US Biosimilars Market Is Heading and When It Might Get There: 2021 Edition”

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.